Design Therapeutics(US:DSGN)2025-11-05 21:10Drug Development - Design Therapeutics plans to initiate patient dosing of DT-818 for Myotonic Dystrophy Type-1 (DM1) in the first half of 2026[1] - DT-818 demonstrated over 90% reduction in toxic RNA foci in DM1 patient cells during preclinical studies[3] - The company continues to advance trials for DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD), with data readouts expected in the second half of 2026[2] - Design Therapeutics has obtained ex-US regulatory clearance for DT-818, marking a significant milestone for the company[1] Financial Performance - Cash and securities totaled $206.0 million as of September 30, 2025, supporting continued pipeline advancement[8] - Research and development (R&D) expenses for Q3 2025 were $14.6 million, compared to $11.9 million in Q3 2024, reflecting a 23% increase[8] - General and administrative (G&A) expenses for Q3 2025 were $4.7 million, slightly up from $4.4 million in Q3 2024[8] - Net loss for Q3 2025 was $17.0 million, compared to a net loss of $13.0 million in Q3 2024, representing a 31% increase[8] - Total operating expenses for Q3 2025 were $19.3 million, up from $16.2 million in Q3 2024, indicating a 13% increase[12] Leadership Changes - The company appointed Justin Gover to its Board of Directors in September 2025, bringing over 25 years of biotechnology leadership experience[8]